Navigation Links
Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007

- Presentations on long-term safety and cardiovascular safety of nebulized formoterol fumarate and safety/ efficacy of concomitant use with tiotropium

for treatment of COPD -

NAPA, Calif., Oct. 16 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), announces three clinical data presentations will be given at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP) on Wednesday, October 24, 2007 at the McCormick Place Convention Center in Chicago. Data will be presented from two safety studies that were included as part of the New Drug Application (NDA) filing to the U.S. Food and Drug Administration (FDA) for Perforomist(TM) Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist(TM) Inhalation Solution with tiotropium for the treatment of COPD.

Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of formoterol fumarate and is indicated for long-term, twice- daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

For those attending CHEST, the three presentations are available as follows:

-- "Long-Term Safety of Nebulized Formoterol in COPD: An Open-Label

Active-Control Extension Study" Poster # 239

-- "Cardiovascular Safety of Nebulized Formoterol in COPD Patients: A

Double-Blind, Placebo-Controlled Study" Poster # 238

-- "Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol

and Tiotropium in COPD," Poster # 251

Poster viewing: Session ID 902 - COPD Treatment II

Wednesday, October 24, 2007, 12:30 - 2:00 PM

Convention Center, Exhibit Hall, McCormick Place, Lakeside Center, Chicago.

Clinical investigators will be available on-site to discuss the research findings.

The research presented at CHEST 2007 was supported through grants provided by Dey, L.P., which developed and markets Perforomist(TM) Inhalation Solution.

About Perforomist(TM) Inhalation Solution


Perforomist(TM) Inhalation Solution is indicated for the long-term, twice- daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information

Perforomist(TM) Inhalation Solution belongs to a class of medications known as long-acting beta2-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active ingredient in Perforomist(TM) Inhalation Solution.

Perforomist(TM) Inhalation Solution should not be used in patients with acutely deteriorating COPD or to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Perforomist(TM) Inhalation Solution should not be used with other medications containing LABAs. Do not use more than one nebule twice daily. Perforomist(TM) Inhalation Solution should be used with caution in patients with cardiovascular disorders. Perforomist(TM) Inhalation Solution is not a substitute for inhaled or oral corticosteroids. The safety and efficacy of Perforomist(TM) Inhalation Solution in asthma has not been established.

In COPD clinical trials, the most common adverse events reported with Perforomist(TM) Inhalation Solution were diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia.

Please see full Prescribing Information, including Boxed Warning, at or call 800-755-5560 and ask for Customer Service.

About COPD

COPD refers to a number of chronic lung disorders in which the airways to the lungs become narrowed and breathing becomes increasingly difficult. The most common forms of COPD are chronic bronchitis and emphysema, and many patients suffer from a combination of the two diseases.

COPD is the fourth leading cause of death in America, behind heart disease, cancer and stroke. Twelve million Americans have been diagnosed with COPD and at least another 12 million have symptoms but are not diagnosed. COPD is not well understood or recognized -- most Americans have not heard of it, not even those who may be living with the condition. The most common cause of COPD is cigarette smoking, which is responsible for an estimated 80 to 90 percent of COPD cases. Estimates of the total incidence of COPD in America range from 24 to 30 million.

About Nebulization

Of the three types of devices used to deliver bronchodilators -- nebulizers, metered-dose inhalers, and dry powder inhalers -- nebulizers require no special technique or coordination, as the medication is converted into a fine mist that the patient inhales through a mouthpiece or face-mask while breathing naturally. Because nebulization is an easy, effective, and thorough method of delivering medicine directly into the lungs, many COPD patients ask for it, particularly as their symptoms worsen.

With Perforomist(TM) Inhalation Solution, nebulization may become a more widely used treatment option for many COPD patients at earlier treatment stages who could benefit from twice-daily maintenance dosing of a nebulized LABA such as Perforomist(TM) Inhalation Solution. For example, this new COPD treatment may be a valuable clinical option for many patients who are not adequately controlled with short-acting bronchodilators.

About Dey, L.P.

Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey, L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey, L.P. include,,,,, and

Perforomist is a trademark of Dey, L.P.

About Mylan

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit

This press release includes statements that constitute "forward-looking statements," including with regard to Perforomist and research results. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the risk that the product may not ultimately prove to be as successful as anticipated; the impact of the competitive COPD environment; and the other risks detailed in the Company's Form 10-Q for the quarter ended June 30, 2007 and its other periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media contacts: Dey, L.P. Media Line

1-800-755-5560 ext. 8363


Harriet Ullman

Feinstein Kean Healthcare


Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
4. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
5. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
6. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
7. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
8. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
9. Data supporting three Antisoma programmes presented at AACR
10. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
11. Genetic Analysis Systems Enter the Clinical Mainstream
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock ... concert posters. This is one of Joplin's most famous and beautiful concert posters. The ... of Michigan in Ann Arbor. The According to Hawley, "It is hard to believe ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
Breaking Medicine News(10 mins):